Mono-Rhamnolipid Biosurfactants Synthesized by Pseudomonas aeruginosa Detrimentally Affect Colorectal Cancer Cells

Over the past 15 years, glycolipid-type biosurfactant compounds have been postulated as novel, naturally synthesized anticancer agents. This study utilized a recombinant strain of to biosynthesize a preparation of mono-rhamnolipids that were purified via both liquid and solid-phase extraction, chara...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-12, Vol.14 (12), p.2799
Main Authors: Twigg, Matthew S, Adu, Simms A, Sugiyama, Suguru, Marchant, Roger, Banat, Ibrahim M
Format: Article
Language:English
Subjects:
anticancer
biosurfactant
Biosynthesis
Breast cancer
Chemotherapy
Colorectal cancer
Cytotoxicity
Fatty acids
Genes
Medical research
Melanoma
Molecular structure
mono-rhamnolipid
Pseudomonas aeruginosa
Surfactants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past 15 years, glycolipid-type biosurfactant compounds have been postulated as novel, naturally synthesized anticancer agents. This study utilized a recombinant strain of to biosynthesize a preparation of mono-rhamnolipids that were purified via both liquid and solid-phase extraction, characterized by HPLC-MS, and utilized to treat two colorectal cancer cell lines (HCT-116 and Caco2) and a healthy colonic epithelial cell line CCD-841-CoN. Additionally, the anticancer activity of these mono-rhamnolipids was compared to an alternative naturally derived anticancer agent, Piceatannol. XTT cell viability assays showed that treatment with mono-rhamnolipid significantly reduced the viability of both colorectal cancer cell lines whilst having little effect on the healthy colonic epithelial cell line. At the concentrations tested mono-rhamnolipids were also shown to be more cytotoxic to the colorectal cancer cells than Piceatannol. Staining of mono-rhamnolipid-treated cells with propidium iodine and acridine orange appeared to show that these compounds induced necrosis in both colorectal cancer cell lines. These data provide an early in vitro proof-of-principle for utilizing these compounds either as active pharmaceutical ingredient for the treatment of colorectal cancer or incorporations into nutraceutical formulations to potentially prevent gastrointestinal tract cancer.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14122799